| 书目名称 | Cardiovascular Safety in Drug Development and Therapeutic Use | | 副标题 | New Methodologies an | | 编辑 | J. Rick Turner,Dilip R. Karnad,Snehal Kothari | | 视频video | http://file.papertrans.cn/222/221984/221984.mp4 | | 概述 | Cutting-edge descriptions and explanations of state-of-the-art cardiovascular safety assessments enable readers to get up to speed quickly. No other book provides such a comprehensive overview of one | | 图书封面 |  | | 描述 | .At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive .in vitro .Proarrhythmia Assay initiative is well under way..Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology..“a resource that will likely serve as a standard for years to come” .- Dr Jonathan Seltzer.Therapeutic Innovation & Regulatory Science., 2017;51(2):180.“I have no hesitation in recommending this book as a valuable reference source” .- Dr Rashmi Shah.Journal for Clinical Studies., 2017;9(1):62-63. | | 出版日期 | Book 2017 | | 关键词 | Proarrhythmic liability; QT interval prolongation; hERG channel blockade; Thorough QT/QTc Study; Regulat | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-319-40347-2 | | isbn_softcover | 978-3-319-82085-9 | | isbn_ebook | 978-3-319-40347-2 | | copyright | Springer International Publishing Switzerland 2017 |
The information of publication is updating
|
|
|Archiver|手机版|小黑屋|
派博传思国际
( 京公网安备110108008328)
GMT+8, 2025-8-16 00:05
发表于 2025-3-21 18:22:43
